Password Reset
Forgot your password? Enter the email address you used to create your account to initiate a password reset.
Forgot your password? Enter the email address you used to create your account to initiate a password reset.
Dear Colleagues,
As we close another remarkable year, I am proud to reflect on the continued excellence of the University of Pittsburgh Department of Neurological Surgery. Our talented faculty and staff have upheld our mission to deliver exceptional patient care, train future neurosurgical leaders, and drive groundbreaking research.
This year, we remained at the forefront of neurosurgical innovation, offering personalized treatments that reflect our commitment to ingenuity and precision. Collaborations within the University of Pittsburgh and our UPMC hospitals have transformed ideas into therapies, advancing care for patients worldwide.
As we look to the future, I am confident that our collective efforts will continue to redefine what is possible in neurosurgery and improve the lives of patients everywhere. I invite you to explore our highlights page to see examples of the outstanding work and dedication of our faculty. Additionally, I encourage you to consider nominating UPMC Presbyterian Shadyside in the 2025 U.S. News & World Report “Best Hospitals” survey. Your support helps us continue to deliver exceptional care and advance the field of neurosurgery.
With gratitude,
Robert M. Friedlander, MD, MA
Chair, Walter E. Dandy Distinguished Professor
Director, Complex Brain Surgery Program
Co-Director, UPMC Neurological Institute
Affiliated with the University of Pittsburgh School of Medicine, UPMC Presbyterian Shadyside is proud to be nationally recognized by U.S. News & World Report for excellence in neurology and neurosurgery.
Spinal Nerve Stimulation Reverses Neuromuscular Disease Progression
Marco Capogrosso, PhD, and Robert Friedlander, MD, were co-corresponding authors of a new study published in Nature Medicine that found that early results from a pilot clinical trial in three human volunteers with spinal muscle atrophy show that one month of regular neurostimulation sessions improved motoneuron function, reduced fatigue and improved strength and walking in all participants, regardless of the severity of their symptoms. The study is first to show that a neurotechnology can be engineered to reverse degeneration of neural circuits and rescue cell function in a human neurodegenerative disease.
Joseph Maroon, MD, Heindl Scholar in Neuroscience at the University of Pittsburgh, along with Mark Lovell, PhD, founding director of the UPMC Sports Concussion Program, received the first-ever Legends of Excellence Award from The Chuck Noll Foundation for Brain Injury Research at the foundation’s inaugural Legends Unite event, held November 18 at Acrisure Stadium’s Hall of Honor Museum in Pittsburgh. The award honored Drs. Maroon and Lovell for their groundbreaking contributions to concussion and brain injury research.
One of the first two grants awarded by the Hunter TBI Program, each in the amount of $100,000, went to the University of Pittsburgh School of Medicine faculty Marco Capogrosso, PhD, assistant professor in the Department of Neurological Surgery.
Dr. Capogrosso’s research primarily focuses on developing new neurotechnologies to stimulate electrodes implanted in the brains of individuals who have experienced a spinal cord injury or stroke to allow them to regain control of their hands after paralysis.
University of Pittsburgh School of Medicine experts analyzed visible signs of concussion in individuals participating in professional slap fighting competitions and reported the results in a paper published in JAMA Surgery. As the first academic study to provide a quantifiable assessment of the possible dangers associated with this activity, the findings offer a starting point for conversations around necessary regulations to ensure participants' long-term health and well-being. Raj Swaroop Lavadi, MBBS, postdoctoral research fellow, was the lead author and Nitin Agarwal, MD, associate professor of neurosurgery, was the senior author.
Jan Drappatz, MD, and Costas Hadjipanyis, MD, PhD, review a case of a neuro-oncology patient at UPMC Hillman Cancer Center and discuss how UPMC Hillman serves as a site for the first clinical trial in the U.S. for photodynamic therapy to treat glioblastoma in this article.
Our Pituitary Center of Excellence is a UPMC Health Plan recognized center with a team of pituitary tumor experts including neurosurgeons, pediatric neurosurgeons, neuroendocrinologists, otolaryngologists, neuroradiologists and neuro-ophthalmologists. Together this team provides multidisciplinary care for pituitary tumors, offering cutting edge care for these diseases. Together with the UPMC Health Plan, they track specific outcomes to ensure that patients get the best care available in the region and the world. Pituitary Centers of Excellence like this have been proven to provide better outcomes, with long term disease control. Our experts can even work with local doctors to guide care wherever it is needed.
Neurosurgeons:
Georgios Zenonos, MD - Co-Director, Center for Skull Base Surgery, Department of Neurological Surgery
Costas Hadjipanyis, MD, PhD - Director, Center for Image-Guided Neurosurgery
L. Dade Lunsford, MD - Pioneer, Gamma Knife Radiosurgery
Researchers from the University of Pittsburgh, UPMC Children’s Hospital of Pittsburgh, and several other institutions have identified a potential new therapeutic target for treating diffuse midline gliomas (DMG), highly aggressive pediatric brain tumors, including diffuse intrinsic pontine glioma, that currently have limited treatment options, dismal prognosis, and have nearly 100% mortality within five years of diagnosis.
The study, titled “An ERK5-PFKFB3 Axis Regulates Glycolysis and Represents a Therapeutic Vulnerability in Pediatric Diffuse Midline Glioma,” was published in Cell Reports.
Sameer Agnihotri, PhD, associate professor of Neurosurgery at the University of Pittsburgh, who directs the Brain Tumor Biology and Therapy Lab at UPMC Children’s was the study’s senior and corresponding author.
A multidisciplinary group of investigators at the University of Pittsburgh and Barrow Neurological Institute in Phoenix created an interactive molecular atlas of traumatic brain injury, or TBI, in mice, which may help doctors use precision medicine to target treatments for TBI patients in the future. This research was published in Neuron.
Gary Kohanbash, PhD, assistant professor of neurological surgery and expert on single-cell RNA sequencing and brain tumor biology in the Department of Neurological Surgery at Pitt was one of the study's co-senior authors.
A multidisciplinary team from the University of Pittsburgh Department of Neurological Surgery, the Department of Pathology at UPMC Children’s Hospital of Pittsburgh, and the Division of Pediatric Hematology/Oncology at UPMC Children’s published a case report in the Asian Journal of Neurosurgery on a case of a 9-year-old patient with a paraspinal desmoid tumor with no prior surgical history.
Robert M. Friedlander, MD, has authored a new review article on Chiari malformation in The New England Journal of Medicine. The review, titled “Congenital and Acquired Chiari Syndrome” was published on June 19, 2024.
David Okonkwo, MD, PhD, has spent two decades developing technologies and treatments to transform management of concussions, traumatic brain injuries, and complex spinal disorders.
His innovation and commercialization efforts have resulted in several medical devices and tests, including the Abbott i-STAT TBI blood test, which helps clinicians evaluate patients 18 years of age and older who show mild traumatic brain injury symptoms.
Baoli Hu, PhD, associate professor of Neurological Surgery at UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine, was awarded a 2024 Richard King Mellon Institute for Pediatric Research Award to support his research on pediatric brain cancer.
A first of its kind clinical trial in the United States to treat glioblastoma launched in early 2024 at UPMC and the UPMC Hillman Cancer Center, which combines intraoperative photodynamic therapy (PDT) with the drug Pentalafen® and a new laser device Heliance®, both, developed by the French company, Hemerion Therapeutics®, sponsor of the clinical trial.
Leading the clinical trial at UPMC is principal investigator Jan Drappatz, MD, associate professor of Medicine in the Division of Hematology/Oncology. Dr. Drappatz also serves as director of the Adult Neuro-Oncology Program and holds a secondary appointment in the Department of Neurology. The neurosurgery co-investigator of the trial is Costas G. Hadjipanayis, MD, PhD, executive vice-chairman and L. Dade Lunsford Professor of Neurological Surgery at the University of Pittsburgh where he also is the director of the Center for Image-Guided Neurosurgery.
UPMC has been a pioneer in image-guided neurosurgery and the use of the Gamma Knife since the early 1980s. In 1981, L. Dade Lunsford, MD, now the Lars Leksell and Distinguished Professor of Neurosurgery at the University of Pittsburgh, orchestrated the world’s first installation of an intraoperative CT scanner at UPMC Presbyterian, kickstarting a revolution in image-guided surgery.
These physicians are part of the Top Doctors® list, which is compiled by Castle Connolly. The Castle Connolly Top Doctor selection process is entirely merit-based with peer-to-peer nominations and a rigorous research process.
(Marco Capogrosso, PhD)
WTAE
February 19, 2025
(Marco Capogrosso, PhD)
AP News
February 5, 2025
View the full list of news articles featuring faculty from the Department.
Traumatic brain injury is a major public health issue, affecting more than 50 million people worldwide each year. Now, a breakthrough rapid blood test has gained FDA approval to help in the earlier diagnosis of mild traumatic brain injuries, which could be difficult to detect until the injury progresses and symptoms become harder to treat. This story features UPMC Director of Neurotrauma David Okonkwo, MD, PhD.